This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event. 

In this week’s episode of The Top Line, Fierce Pharma’s Zoey Becker and Angus Liu join Fierce Biotech’s Darren Incorvaia to break down the biggest news stories out of the conference. From Johnson & Johnson’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week just days before she left the White House, this year’s conference set the stage for what will surely be an eventful 2025.

To learn more about the topics in this episode:
‘Own JP Morgan, don't let JP Morgan own you’: Biopharma—and Jill Biden—show up for JPM25
JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B
JPM25: First Lady Jill Biden committed to improving women's health as White House tenure winds down
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset

This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.

This year&rsquo;s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event.&nbsp;
In this week&rsquo;s episode of The Top Line, Fierce Pharma&rsquo;s Zoey Becker and Angus Liu join Fierce Biotech&rsquo;s Darren Incorvaia to break down the biggest news stories out of the conference. From Johnson &amp; Johnson&rsquo;s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden&rsquo;s appearance at Fierce JPM Week just days before she left the White House, this year&rsquo;s conference set the stage for what will surely be an eventful 2025.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/own-jp-morgan-dont-let-jp-morgan-own-you-biopharma-and-jill-biden-show-jpm25">&lsquo;Own JP Morgan, don't let JP Morgan own you&rsquo;: Biopharma&mdash;and Jill Biden&mdash;show up for JPM25</a></li>
<li><a href="https://www.fiercepharma.com/pharma/johnson-johnson-makes-jpm-splash-buying-out-intra-cellular-146b?_gl=1*1omg757*_gcl_au*NzA3ODU2NjE4LjE3MzU4Mjk0MDg.*_ga*NTI1OTIyMzk5LjE3MTk5MjkwNDM.*_ga_KG49J84SR4*MTczNzE0MjM3Mi4zLjEuMTczNzE0NDQwNS4wLjAuMA..">JPM25: Johnson &amp; Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B</a></li>
<li><a href="https://www.fiercehealthcare.com/regulatory/jpm25-first-lady-jill-biden-committed-improving-womens-health-white-house-tenure-winds">JPM25: First Lady Jill Biden committed to improving women's health as White House tenure winds down</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/jpm25-strategist-gsk-acquires-idrx-1b-hopes-bringing-gist-patients-new-standard-care">JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/gsk-backed-ouro-medicines-launches-t-cell-engager-space-115m-and-clinical-stage-asset">GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset</a></li>
</ul>
This episode is brought to you by Cencora. Learn more at&nbsp;<a href="https://www.cencora.com/initiatives/pharma/supporting-biopharma-breakthroughs?utm_source=FiercePharma&amp;utm_medium=audio&amp;utm_campaign=gps_100_awareness&amp;utm_content=breakthrough-emerging">cencora.com/breakthrough</a>.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement